Uptravi Delays Progression of PAH Associated with Lupus and Other Connective Tissue Diseases, Trial Shows
Uptravi (selexipag) delays the progression of pulmonary arterial hypertension in people with PAH that is associated with connective tissue diseases, including lupus, a Phase 3 clinical trial shows. Patients also tolerate Uptravi well, researchers said. PAH associated with connective tissue disease is also known as PAH-CTD, and PAH associated with lupus…